Abstract
Recent clinical trials of immunotherapies indicate that tumor reactive autologous T cells are able to regress even advanced, large tumors in melanoma patients. For example, the adoptive transfer of CD8+ cytotoxic T lymphocytes (CTL) specifically targeted for identified tumor antigens following lymphodepletive treatment, such as fludarabine/cyclophosphamide administration and total body irradiation, led to objective tumor responses in more than 70% of patients with melanoma (Dudley et al. 2008). Immunological analyses on these tumor tissues demonstrated that administered T cells may eliminate tumor cells through direct killing and cytokine secretion. Therefore, CD8+ CTLs that recognize MHC class I positive cancer cells are important for in vivo tumor rejection.
| Original language | English |
|---|---|
| Title of host publication | Innate Immune Regulation and Cancer Immunotherapy |
| Publisher | Springer New York |
| Pages | 335-345 |
| Number of pages | 11 |
| ISBN (Print) | 9781441999146, 9781441999139 |
| DOIs | |
| Publication status | Published - 2012 Jan 1 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Human tumor antigens recognized by T cells and their implications for cancer immunotherapy. / Ueda, Ryo; Yaguchi, Tomonori; Kawakami, Yutaka.
Innate Immune Regulation and Cancer Immunotherapy. Springer New York, 2012. p. 335-345.Research output: Chapter in Book/Report/Conference proceeding › Chapter
}
TY - CHAP
T1 - Human tumor antigens recognized by T cells and their implications for cancer immunotherapy
AU - Ueda, Ryo
AU - Yaguchi, Tomonori
AU - Kawakami, Yutaka
PY - 2012/1/1
Y1 - 2012/1/1
N2 - Recent clinical trials of immunotherapies indicate that tumor reactive autologous T cells are able to regress even advanced, large tumors in melanoma patients. For example, the adoptive transfer of CD8+ cytotoxic T lymphocytes (CTL) specifically targeted for identified tumor antigens following lymphodepletive treatment, such as fludarabine/cyclophosphamide administration and total body irradiation, led to objective tumor responses in more than 70% of patients with melanoma (Dudley et al. 2008). Immunological analyses on these tumor tissues demonstrated that administered T cells may eliminate tumor cells through direct killing and cytokine secretion. Therefore, CD8+ CTLs that recognize MHC class I positive cancer cells are important for in vivo tumor rejection.
AB - Recent clinical trials of immunotherapies indicate that tumor reactive autologous T cells are able to regress even advanced, large tumors in melanoma patients. For example, the adoptive transfer of CD8+ cytotoxic T lymphocytes (CTL) specifically targeted for identified tumor antigens following lymphodepletive treatment, such as fludarabine/cyclophosphamide administration and total body irradiation, led to objective tumor responses in more than 70% of patients with melanoma (Dudley et al. 2008). Immunological analyses on these tumor tissues demonstrated that administered T cells may eliminate tumor cells through direct killing and cytokine secretion. Therefore, CD8+ CTLs that recognize MHC class I positive cancer cells are important for in vivo tumor rejection.
UR - http://www.scopus.com/inward/record.url?scp=84955389375&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84955389375&partnerID=8YFLogxK
U2 - 10.1007/9781441999146_19
DO - 10.1007/9781441999146_19
M3 - Chapter
SN - 9781441999146
SN - 9781441999139
SP - 335
EP - 345
BT - Innate Immune Regulation and Cancer Immunotherapy
PB - Springer New York
ER -